Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.3% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in CRISPR/Cas9-based therapies for genetic diseases. The stock saw a significant increase in value today amidst recent market developments.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.3% on Nov 12, 2025 14:41

• NTLA reported a narrowed Q3 loss, but the stock declined after the company withdrew guidance on a key pipeline milestone, sparking concerns about FDA scrutiny in amyloidosis patients.
• The company fell short of revenue expectations for the quarter, which may have initially contributed to negative market sentiment.
• Despite these setbacks, investors have responded positively to the progress and potential of NTLA's CRISPR-based therapies, driving the stock's upward movement today.
• The market appears to be reevaluating Intellia Therapeutics' long-term outlook, taking into account the potential impact of their innovative genetic disease treatments despite short-term challenges.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Brighthouse Finl ( NASDAQ:BHF ) , Bath & Body Works ( NYSE:BBWI )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

https://www.benzinga.com/analyst-stock-ratings/downgrades/25/11/48802086/this-bath-body-works-analyst-is-no-longer-bullish-here-are-top-4-downgrades-for-

This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - SPS Commerce ( NASDAQ:SPSC ) , Intellia Therapeutics ( NASDAQ:NTLA )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

https://www.benzinga.com/analyst-stock-ratings/downgrades/25/11/48776077/this-sps-commerce-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-tue

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.

https://www.zacks.com/stock/news/2787874/intellia-q3-loss-narrower-than-expected-stock-down-on-pipeline-trouble

Intellia Therapeutics, Inc. ( NTLA ) Reports Q3 Loss, Misses Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +9.80% and -12.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2787192/intellia-therapeutics-inc-ntla-reports-q3-loss-misses-revenue-estimates

Trending Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 6.6% Today

UnitedHealth Group Incorporated (DE) ($UNH) Stock Forecast: Up 5.4% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.3% Today

Baxter International Inc. ($BAX) Stock Forecast: Up 5.1% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 6.1% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 5.6% Today

Amdocs Limited ($DOX) Stock Forecast: Down 5.0% Today

GlobalFoundries Inc. ($GFS) Stock Forecast: Up 6.2% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 6.2% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.9% Today

Intellia Therapeutics, Inc. Price History

22.08.2025 - NTLA Stock was up 5.8%

• The stock of NTLA showed a strong bullish movement today.
• The completion of enrollment in the pivotal phase III HAELO study on lonvo-z for hereditary angioedema led to a nearly 30% surge in Intellia shares.
• Positive longer-term data from the ongoing Phase 1 clinical trial of Nexiguran Ziclumeran for the treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy also increased investor confidence.
• The expectation of Phase 3 topline data in the first half of 2026 further added to the positive sentiment surrounding Intellia Therapeutics.

22.09.2025 - NTLA Stock was down 6.5%

• The bearish movement in NTLA's stock today could be due to concerns about the competition in the gene editing space.
• Investors may be cautious about the company's ability to maintain a competitive edge in the market, especially with the focus on its in vivo pipeline for long-term growth.
• The market might be reacting to uncertainties surrounding the success and commercialization of Intellia's late-stage gene-editing therapies, lonvo-z and nex-z.
• Overall, the negative market sentiment towards NTLA today could be influenced by doubts about the company's future growth prospects amidst a competitive landscape in the gene editing industry.

28.09.2025 - NTLA Stock was down 6.8%

• The downward movement in NTLA stock could be tied to the overall negative sentiment in the biotechnology sector, possibly influenced by the recent downgrade of Boot Barn Holdings Inc. by a prominent Wall Street analyst.
• This shift in analyst perspective may have impacted investor trust in the sector, resulting in a sell-off of NTLA shares.
• Investors appear to be exercising caution regarding the future potential of gene editing technologies, including CRISPR/Cas9, in light of recent analyst actions and broader market patterns.

08.09.2025 - NTLA Stock was up 25.1%

• Analysts on Wall Street foresee a 63.7% upside potential for NTLA, reflecting favorable sentiment towards the stock.
• The company disclosed inducement grants in line with Nasdaq Listing Rule 5635, highlighting efforts to attract top talent and foster innovation.
• The rising trend in earnings estimate revisions may have contributed to the stock's bullish performance.
• Overall, positive developments and optimistic analyst projections appear to have propelled the strong bullish trend in Intellia Therapeutics' stock today.

30.09.2025 - NTLA Stock was down 9.8%

• Intellia Therapeutics (NTLA) stock saw a significant drop in after-hours trading subsequent to the FDA's decision to place a clinical hold on some of its Investigational New Drug applications.
• The regulatory setback from the FDA has likely caused concerns among investors regarding potential delays in the company's drug development pipeline and its financial implications.
• This news prompted a sell-off as investors reassessed Intellia Therapeutics' short-term outlook, leading to a notable decrease in NTLA stock price.
• The bearish trend in NTLA stock may continue until there is more clarity on the FDA's issues and the company's plan to address them, underscoring the significance of regulatory risks in the biotech sector.

09.09.2025 - NTLA Stock was up 5.1%

• NTLA experienced a significant increase of 19.7% in its shares, accompanied by above-average trading volume.
• Analysts from Wall Street are optimistic about NTLA, projecting a potential upside of 63.7% for the stock, reflecting favorable market sentiment.
• Recent changes in earnings estimates for Intellia Therapeutics may have contributed to the price surge, hinting at further growth in the short term.
• The company disclosed the provision of inducement grants under Nasdaq Listing Rule 5635 (c)(4), potentially enhancing investor confidence in the company's future prospects.

25.08.2025 - NTLA Stock was down 5.3%

• Despite positive progress on key clinical studies, the market response may have been dampened by the absence of immediate revenue-generating activities or commercialization opportunities.
• Investors could be capitalizing on recent stock price gains following a successful enrollment completion in a pivotal study for lonvo-z in hereditary angioedema.
• Concerns surrounding the timeline for Phase 3 data release in 2026 might have contributed to a shift in market sentiment, prompting a sell-off of the stock.
• The general downward trend could also be a result of broader market conditions or sector rotations affecting biotech stocks, leading traders to reassess their positions in NTLA.

07.09.2025 - NTLA Stock was down 5.4%

• The drop in NTLA stock could be a result of investors taking profits following a recent increase in the stock's value.
• Concerns among investors about the potential dilution of current shares due to the announcement of inducement grants may have triggered a sell-off.
• Investors could be reexamining their positions in NTLA stock due to apprehensions about competition within the gene editing industry.

11.10.2025 - NTLA Stock was down 5.6%

• NTLA stock dropped despite posting a reduced loss in Q3, attributed to challenges in its pipeline and retracting guidance amidst FDA investigation in amyloidosis patients.
• Revenue for the quarter fell short of expectations, likely impacting investor sentiment negatively.
• Analysts revising their projections for the stock to a more pessimistic view also contributed to the decline in NTLA shares.
• Uncertainties related to the FDA investigation and the company's pipeline setbacks appeared to outweigh any positive aspects of the earnings report, resulting in a significant drop in stock price.

12.10.2025 - NTLA Stock was up 5.3%

• NTLA reported a narrowed Q3 loss, but the stock declined after the company withdrew guidance on a key pipeline milestone, sparking concerns about FDA scrutiny in amyloidosis patients.
• The company fell short of revenue expectations for the quarter, which may have initially contributed to negative market sentiment.
• Despite these setbacks, investors have responded positively to the progress and potential of NTLA's CRISPR-based therapies, driving the stock's upward movement today.
• The market appears to be reevaluating Intellia Therapeutics' long-term outlook, taking into account the potential impact of their innovative genetic disease treatments despite short-term challenges.

07.10.2025 - NTLA Stock was down 24.0%

• NTLA disclosed a Q3 loss and revenue estimates were not met, signifying financial underperformance.
• The adverse earnings surprise and revenue shortfall probably influenced investor apprehensions and the downward trend in the stock price.
• Investors might be wary about the company's future outlook and the implications of these financial outcomes on its pipeline and growth opportunities.

07.10.2025 - NTLA Stock was down 27.2%

• A recent decrease in Q3 losses did not prevent a significant bearish trend in NTLA stock. This was notably influenced by the company retracting guidance on a crucial pipeline milestone and encountering FDA scrutiny regarding amyloidosis patients.
• Despite the company's Q3 loss and revenue missing estimates, investor confidence dwindled further.
• Concerns over FDA scrutiny and uncertainty about the company's milestone achievements may have spurred a wave of sell-offs for NTLA stock.
• Investors are likely reassessing NTLA's future based on financial performance and regulatory obstacles, consequently amplifying the downward pressure on the stock price.